866-997-4948(US-Canada Toll Free)

Herpes Simplex Infections - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Diseases & Conditions

No. of Pages : 154 Pages


This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Herpes Simplex Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Herpes Simplex Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Herpes Simplex Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Herpes Simplex Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Herpes Simplex Infections Overview 8
Therapeutics Development 9
Pipeline Products for Herpes Simplex Infections Overview 9
Pipeline Products for Herpes Simplex Infections Comparative Analysis 10
Herpes Simplex Infections Therapeutics under Development by Companies 11
Herpes Simplex Infections Therapeutics under Investigation by Universities/Institutes 15
Herpes Simplex Infections Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Herpes Simplex Infections Products under Development by Companies 20
Herpes Simplex Infections Products under Investigation by Universities/Institutes 22
Herpes Simplex Infections Companies Involved in Therapeutics Development 23
Vical Incorporated 23
Sanofi 24
GenVec, Inc. 25
Astellas Pharma Inc. 26
CEL-SCI Corporation 27
Mymetics Corporation 28
NovaBay Pharmaceuticals, Inc. 29
Nutra Pharma Corporation 30
Peregrine Pharmaceuticals, Inc. 31
Oryzon Genomics S.A. 32
Colby Pharmaceutical Company 33
Osel Inc. 34
AlphaVax, Inc. 35
Romark Laboratories, L.C. 36
Chimerix, Inc. 37
NanoBio Corporation 38
Immunovaccine, Inc. 39
Immune Design Corp. 40
Seek 41
Adamis Pharmaceuticals Corporation 42
Vaxart, Inc. 43
Genocea Biosciences, Inc. 44
Profectus BioSciences, Inc. 45
3-V Biosciences, Inc. 46
Spider Biotech S.r.l. 47
Kala Pharmaceuticals, Inc. 48
Coridon Pty Ltd 49
Sanofi Pasteur SA 50
Humabs BioMed SA 51
BioApex, s.r.o. 52
Herpes Simplex Infections Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Target 55
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 63
Drug Profiles 66
amenamevir - Drug Profile 66
tenofovir - Drug Profile 67
RPI-78M - Drug Profile 69
RPI-MN - Drug Profile 71
HSV-2 Vaccine - Drug Profile 73
GEN-003 - Drug Profile 75
Herpes Simplex Virus Type 2 Vaccine - Drug Profile 77
HSV-529 - Drug Profile 78
ID-G103 - Drug Profile 80
brincidofovir - Drug Profile 81
CEL-1000 - Drug Profile 83
HSV Vaccine - Drug Profile 85
HSV-2 Vaccine - Drug Profile 86
C-31-G - Drug Profile 87
MucoCept Platform - Drug Profile 89
HSV-2 Px - Drug Profile 90
NVC-727 - Drug Profile 91
JVRS-100 + Herpes Simplex Virus-2 Vaccine - Drug Profile 92
Drug for Herpes Simplex - Drug Profile 94
PGN-632 - Drug Profile 95
GV-2207 - Drug Profile 96
acyclovir - Drug Profile 97
SB-105 - Drug Profile 98
Plantibodies - Drug Profile 99
Azuvirins - Drug Profile 100
Herpes Simplex Virus Vaccine - Drug Profile 101
MB-66 - Drug Profile 102
Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - Drug Profile 103
BA-368 - Drug Profile 104
HSV-2 Vaccine - Drug Profile 105
RKP-00156 - Drug Profile 106
CEL-1000 - Drug Profile 107
MAb hu2c - Drug Profile 108
HSV Vaccine - Drug Profile 109
Therapeutic/Prophylactic Vaccine Program For Herpes Simplex Virus - Drug Profile 110
New Thiazolides - Drug Profile 111
Small Molecule To Inhibit LSD-1 For HSV - Drug Profile 112
ELS-120 - Drug Profile 113
RC-100b - Drug Profile 114
Drug For Herpes Simplex Virus - Drug Profile 116
Subunit Vaccine for Herpes Simplex Virus 2 - Drug Profile 117
Small Molecules for Viral Infections - Drug Profile 118
MAb Against HSV-1/2 - Drug Profile 119
Labyrinthopeptine A1 - Drug Profile 120
Lipopeptide Vaccine For HSV Infections - Drug Profile 121
Small Molecules for Viral Infections - Drug Profile 122
Small Molecules for Bacterial and Viral Infections - Drug Profile 123
Herpes Simplex Infections Recent Pipeline Updates 124
Herpes Simplex Infections Dormant Projects 139
Herpes Simplex Infections Discontinued Products 140
Herpes Simplex Infections Product Development Milestones 141
Featured News & Press Releases 141

Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151

List of Table


Number of Products under Development for Herpes Simplex Infections, H1 2014 12
Number of Products under Development for Herpes Simplex Infections Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Development by Companies, H1 2014 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Development, H1 2014 22
Products under Development by Companies, H1 2014 23
Products under Development by Companies, H1 2014 (Contd..1) 24
Products under Investigation by Universities/Institutes, H1 2014 25
Herpes Simplex Infections Pipeline by Vical Incorporated, H1 2014 26
Herpes Simplex Infections Pipeline by Sanofi, H1 2014 27
Herpes Simplex Infections Pipeline by GenVec, Inc., H1 2014 28
Herpes Simplex Infections Pipeline by Astellas Pharma Inc., H1 2014 29
Herpes Simplex Infections Pipeline by CEL-SCI Corporation, H1 2014 30
Herpes Simplex Infections Pipeline by Mymetics Corporation, H1 2014 31
Herpes Simplex Infections Pipeline by NovaBay Pharmaceuticals, Inc., H1 2014 32
Herpes Simplex Infections Pipeline by Nutra Pharma Corporation, H1 2014 33
Herpes Simplex Infections Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 34
Herpes Simplex Infections Pipeline by Oryzon Genomics S.A., H1 2014 35
Herpes Simplex Infections Pipeline by Colby Pharmaceutical Company, H1 2014 36
Herpes Simplex Infections Pipeline by Osel Inc., H1 2014 37
Herpes Simplex Infections Pipeline by AlphaVax, Inc., H1 2014 38
Herpes Simplex Infections Pipeline by Romark Laboratories, L.C., H1 2014 39
Herpes Simplex Infections Pipeline by Chimerix, Inc., H1 2014 40
Herpes Simplex Infections Pipeline by NanoBio Corporation, H1 2014 41
Herpes Simplex Infections Pipeline by Immunovaccine, Inc., H1 2014 42
Herpes Simplex Infections Pipeline by Immune Design Corp., H1 2014 43
Herpes Simplex Infections Pipeline by Seek, H1 2014 44
Herpes Simplex Infections Pipeline by Adamis Pharmaceuticals Corporation, H1 2014 45
Herpes Simplex Infections Pipeline by Vaxart, Inc., H1 2014 46
Herpes Simplex Infections Pipeline by Genocea Biosciences, Inc., H1 2014 47
Herpes Simplex Infections Pipeline by Profectus BioSciences, Inc., H1 2014 48
Herpes Simplex Infections Pipeline by 3-V Biosciences, Inc., H1 2014 49
Herpes Simplex Infections Pipeline by Spider Biotech S.r.l., H1 2014 50
Herpes Simplex Infections Pipeline by Kala Pharmaceuticals, Inc., H1 2014 51
Herpes Simplex Infections Pipeline by Coridon Pty Ltd, H1 2014 52
Herpes Simplex Infections Pipeline by Sanofi Pasteur SA, H1 2014 53
Herpes Simplex Infections Pipeline by Humabs BioMed SA, H1 2014 54
Herpes Simplex Infections Pipeline by BioApex, s.r.o., H1 2014 55
Assessment by Monotherapy Products, H1 2014 56
Assessment by Combination Products, H1 2014 57
Number of Products by Stage and Target, H1 2014 60
Number of Products by Stage and Mechanism of Action, H1 2014 63
Number of Products by Stage and Route of Administration, H1 2014 65
Number of Products by Stage and Molecule Type, H1 2014 68
Herpes Simplex Infections Therapeutics Recent Pipeline Updates, H1 2014 127
Herpes Simplex Infections Dormant Projects, H1 2014 142
Herpes Simplex Infections Discontinued Products, H1 2014 143

List of Chart


Number of Products under Development for Herpes Simplex Infections, H1 2014 12
Number of Products under Development for Herpes Simplex Infections Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 18
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Comparative Analysis by Early Stage Products, H1 2014 22
Assessment by Monotherapy Products, H1 2014 56
Number of Products by Top 10 Target, H1 2014 58
Number of Products by Stage and Top 10 Target, H1 2014 59
Number of Products by Top 10 Mechanism of Action, H1 2014 61
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 62
Number of Products by Top 10 Route of Administration, H1 2014 64
Number of Products by Stage and Top 10 Route of Administration, H1 2014 65
Number of Products by Top 10 Molecule Type, H1 2014 66
Number of Products by Stage and Top 10 Molecule Type, H1 2014 67

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *